The skin in autoimmune diseases-Unmet needs

Area of Science:

• Rheumatology
• Dermatology
• Immunology

Background:

• Current treatments for skin issues in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and dermatomyositis (DM) lack robust evidence from randomized controlled trials.
• While antimalarials are first-line for SLE, some patients are resistant, and newer therapies like belimumab lack validated skin outcome measures.
• Therapeutic options for skin sclerosis and digital ulcers in SSc are limited, and DM skin lesions often worsen with reduced immunosuppressive or corticosteroid therapy.

Purpose of the Study:

• To highlight the unmet need for effective treatments targeting skin manifestations in systemic autoimmune diseases.
• To emphasize the necessity of innovative clinical trial designs and validated skin scoring systems.
• To advocate for the development of novel therapeutic strategies for cutaneous involvement in SLE, SSc, and DM.

Main Methods:

• Review of existing literature on treatment efficacy for cutaneous manifestations in SLE, SSc, and DM.
• Analysis of current therapeutic approaches and their limitations.
• Identification of the need for validated skin outcome measures in clinical trials.

Main Results:

• Few randomized controlled trials exist for treating skin manifestations in these diseases.
• Existing treatments show variable efficacy and limitations, particularly for SSc and DM skin lesions.
• There is a significant gap in validated skin assessment tools for evaluating treatment effectiveness, such as for belimumab in SLE.

Conclusions:

• A high unmet need exists for novel therapeutic strategies for skin involvement in systemic autoimmune diseases.
• Innovative randomized controlled trial designs incorporating validated skin scores are essential.
• Developing new treatments for cutaneous manifestations in SLE, SSc, and DM requires a focus on rigorous clinical evaluation.